Defining a dose–response relationship for prostate external beam radiotherapy
- 28 December 2012
- journal article
- research article
- Published by Wiley in Journal of Medical Imaging and Radiation Oncology
- Vol. 57 (2) , 237-246
Abstract
Introduction: We aimed to quantify a relationship between radiotherapy dose and freedom from biochemical failure (FFBF) in low‐ and intermediate‐risk prostate cancer. To reduce confounding we used data with a standardised end–point, mature follow‐up, low competing risk of metastatic failure, conventional fractionation and separate reporting for outcomes with hormonal therapy (HT).Methods: A systematic review of the literature was carried out. Studies that reported the use of radiotherapy alone in 1.8–2 Gy fractions in low‐ and intermediate‐risk prostate cancer were included. The primary end–point was Phoenix definition 5‐year FFBF. A logistic regression was used to quantify the dose–response relationship.Results: Data from eight studies with 3037 patients met the inclusion criteria. The data from 810 low‐risk patients and 2245 intermediate‐risk patients were analysed. A strong association between radiotherapy dose and FFBF was found in low‐ and intermediate‐risk patients managed with radiotherapy alone. In low‐risk patients not treated with HT the dose required to achieve 50% biochemical tumour control (TCD50) is 52.0 Gy and the slope of the dose–response curve at TCD50 (γ50) is 2.1%/Gy. At 78 Gy this represented a FFBF of 90.3%. In intermediate‐risk patients not treated with HT the TCD50 is 64.7 Gy and γ50 is 3.2%/Gy. At 78 Gy this translated into a FFBF of 84.3%. HT had a small effect for low‐risk patients and an inconsistent effect for intermediate‐risk men.Conclusion: A strong association was found between radiation dose and biochemical outcome in both low‐ and intermediate‐risk patients. Standardised reporting of results from future studies will make future analyses more robust.Keywords
This publication has 40 references indexed in Scilit:
- Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Carcinoma: Final Results of Phase III Randomized TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate CancerNew England Journal of Medicine, 2011
- Lack of Benefit for the Addition of Androgen Deprivation Therapy to Dose-Escalated Radiotherapy in the Treatment of Intermediate- and High-Risk Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- 70 Gy Versus 80 Gy in Localized Prostate Cancer: 5-Year Results of GETUG 06 Randomized TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Pharmacotherapeutic Management of Locally Advanced Prostate CancerDrugs, 2011
- A New Method for Synthesizing Radiation Dose–Response Data From Multiple Trials Applied to Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Randomized Trial Comparing Conventional-Dose With High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results From Proton Radiation Oncology Group/American College of Radiology 95-09Journal of Clinical Oncology, 2010
- Image guided dose escalated prostate radiotherapy: still room to improveRadiation Oncology, 2009
- What Dose of External-Beam Radiation is High Enough for Prostate Cancer?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Dosimetric comparison of four target alignment methods for prostate cancer radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006